Biogen, Inc. Hits New 52-Week High at USD 206.66

Biogen, Inc., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 206.66 on June 25, 2026. This achievement marks a notable rebound from its 52-week low of USD 121.05, showcasing the stock's recent upward momentum. Despite a challenging year, with a 1-year performance of -10.63%, Biogen's current price reflects a strong market position within its industry. The company boasts a market capitalization of USD 31,355 million and a price-to-earnings (P/E) ratio of 17.00, indicating a competitive valuation relative to its earnings. Additionally, Biogen maintains a low debt-to-equity ratio of 0.14, suggesting a solid financial foundation. The company's return on equity stands at 10.01%, further emphasizing its ability to generate profit from shareholders' equity. With no dividend yield currently offered, investors may be focused on capital appreciation as Biogen continues to navigate the evolving landscape of the pharmaceuticals and biotechnology industry.